We are live on ! Find out more
AFM

Anson Funds Management Portfolio holdings

AUM $2.29B
1-Year Est. Return 370.24%
This Fund
S&P 500
This Quarter Est. Return
-47.2%
1 Year Est. Return
+370.24%
3 Year Est. Return
+1,243.07%
5 Year Est. Return
+867.54%
10 Year Est. Return
+12,575.88%
AUM
$172M
AUM Growth
-$108M
Cap. Flow
+$5.75M
Cap. Flow %
3.34%
Top 10 Hldgs %
91.48%
Holding
64
New
48
Increased
–
Reduced
2
Closed
10

Top Buys

Rank Stock Value
1
AGX icon
Argan
AGX
+$1.83M
2
BPYU
Brookfield Property REIT Inc. Class A Common Stock
BPYU
+$1.73M
3
VLRX
VALERITAS HOLDINGS INC
VLRX
+$1.39M
4
VRE
Veris Residential
VRE
+$890K
5
CSCI
COSCIENS Biopharma Inc. Common Stock
CSCI
+$803K

Top Sells

Rank Stock Value
1
AMRWW
Alta Mesa Resources Inc Warrant
AMRWW
+$2.6M
2
VANIW
Vivani Medical, Inc. Warrants expiring 03/14/2024
VANIW
+$2.54M
3
AMR
Alta Mesa Resources Inc
AMR
+$2.51M
4
ATAXZ
AMERICA FIRST TAX EXEMT INV LP
ATAXZ
+$1.63M
5
PAVMZ
PAVmed Inc. Series Z Warrant
PAVMZ
+$1.46M

Sector Composition

Rank Sector Weight
1 Healthcare 61.93%
2 Real Estate 2.79%
3 Industrials 0.95%
4 Technology 0.53%
5 Consumer Staples 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTEA
26
DELISTED
DAVIDsTEA Inc. Common Stock
DTEA
$385K 0.22%
+326,414
New +$707K
TTPH
27
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$380K 0.22%
+16,797
New +$657K
LPT
28
DELISTED
Liberty Property Trust
LPT
$377K 0.22%
+9,000
New +$388K
UXIN
29
CALL
Uxin Ltd
UXIN
$332M
$374K 0.22%
+769
New +$445K
INFI
30
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$346K 0.2%
+293,427
New +$528K
CYTXZ
31
DELISTED
Cytori Therapeutics Inc Series S Warrant
CYTXZ
$301K 0.17%
1,038,600
– –
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
$298K 0.17%
+174,174
New +$523K
FRAN
33
DELISTED
Francesca's Holdings Corporation
FRAN
$297K 0.17%
+25,492
New +$742K
FOMX
34
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$284K 0.17%
+79,061
New +$344K
RESN
35
DELISTED
Resonant Inc.
RESN
$280K 0.16%
+210,631
New +$514K
VIVE
36
DELISTED
VIVEVE MED INC
VIVE
$263K 0.15%
+250
New +$600K
CLSD
37
DELISTED
Clearside Biomedical
CLSD
$250K 0.15%
+15,559
New +$730K
CLDX icon
38
Celldex Therapeutics
CLDX
$2.77B
$243K 0.14%
+81,990
New +$403K
ONCT
39
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$207K 0.12%
+1,894
New +$379K
ACC
40
DELISTED
American Campus Communities, Inc.
ACC
$207K 0.12%
+5,000
New +$207K
ALAR
41
Alarum Technologies
ALAR
$13.2M
$190K 0.11%
+320
New +$399K
RKDA icon
42
Arcadia Biosciences
RKDA
$1.41M
$175K 0.1%
+1,383
New +$232K
GERN icon
43
Geron
GERN
$917M
$171K 0.1%
+171,203
New +$260K
TCON
44
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$158K 0.09%
+1,251
New +$340K
SISI
45
DELISTED
Shineco
SISI
$94K 0.05%
+1
New +$79.5K
TOVX icon
46
Theriva Biologics
TOVX
$9.46M
$88K 0.05%
+628
New +$149K
PDSB icon
47
PDS Biotechnology
PDSB
$38.3M
$78K 0.05%
+12,171
New +$161K
PHIOW
48
DELISTED
Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021
PHIOW
$72K 0.04%
+217,023
New +$8.66K
TNXP icon
49
Tonix Pharmaceuticals
TNXP
$164M
– –
0
– –
CRVO icon
50
CervoMed
CRVO
$23.1M
$66K 0.04%
+442
New +$151K
1
2
3

Similar funds

RA
RPOA Advisors Plano, Texas $2.29B AUM 11.74% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
ST
Smithfield Trust Pittsburgh, Pennsylvania $2.3B AUM 14.87% 1-Year Est. Return
GCP
Greenoaks Capital Partners Orinda, California $2.3B AUM 19.87% 1-Year Est. Return
LCM
Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.27B AUM

Anson Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Anson Funds Management held 64 positions worth $172M, down 39% from $280M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Anson Funds Management deployed $5.75M of net new capital in Q4 2018, opening 48 new positions. Its largest new stake was Argan: 43,385 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 73% a quarter earlier, followed by Real Estate and Industrials.

On the sell side, the largest reduction was Ontrak, an estimated $533K trimmed.

  • Anson Funds Management's largest Q4 2018 buy was Argan: 43,385 shares worth $1.64M.
  • Anson Funds Management's biggest Q4 2018 reduction was Ontrak, cutting an estimated $533K.
  • Anson Funds Management fully exited Alta Mesa Resources Inc Warrant in Q4 2018, selling an estimated $2.6M.
  • Anson Funds Management's ten largest holdings make up 91% of its $172M portfolio in Q4 2018.
  • Anson Funds Management opened 48 new positions and closed 10 in Q4 2018.
  • Anson Funds Management's portfolio value fell 39% quarter-over-quarter to $172M.

Based on Anson Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.